logo-loader
HealthPharma & Biotech
Bard1 Life Sciences Ltd

BARD1 Life Sciences shares surge after positive ovarian cancer test

The BARD1 ovarian cancer test is an ELISA-based blood test.

rsz_shutterstock_314242085.jpg
The test detected all stages of ovarian cancer

BARD1 Life Sciences (ASX:BD1) shares were trading 110% higher intra-day after successfully completing a clinical trial of its proprietary ovarian cancer diagnostic test.

The trial involving 348 samples (200 women with ovarian cancer and 148 controls) found the test to have both high specificity (87%) and high sensitivity (90%).

In addition, the test detected all subtypes and stages of ovarian cancer in the samples with the performance of the test between early-stage and late stage ovarian cancer not statistically different.

The BARD1 Ovarian Cancer Test is an ELISA-based blood test that uses a panel of peptides on a solid surface.

When exposed to a blood sample, the test measures the binding of antibodies in the patient’s blood to these peptides.

Previous data from smaller scale studies had already established the proof of concept of the test and initial indications of high sensitivity and specificity.

With high levels of accuracy shown to all stages of ovarian cancer, the BARD1 test may offer a substantial improvement over existing ovarian cancer blood tests.

The test is expected to improve the accurate detection of cancer at all stages with few false positives.

Further studies are planned to demonstrate the use of the BARD1 Ovarian Cancer Test for distinction of benign ovarian lesions and cancer.

The company is also focused on its lead product, the BARD1 Lung Cancer Test, for early detection of lung cancer utilising novel tumour markers and a proprietary algorithm.

BARD1’s closing cash balance as at 31 December 2016 was circa $1.93 million.

Quick facts: Bard1 Life Sciences Ltd

Price: $0.03

Market: ASX
Market Cap: $46.48 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CB2 Insights licenses electronic data capture software to UK...

CB2 Insights (CSE:CBII-OTCQB: CBIIF) CEO Prad Sekar joined Steve Darling from Proactive Vancouver to discuss the company doing a deal with MYACCESS Clinics. This will allow CB2’s software to capture comprehensive data sets related to patient health and treatment histories and manage ongoing...

1 day, 7 hours ago

2 min read